Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest

Simply Wall St.06-15

AdvertisementPhase 2 PWS data and what it could mean for Rhythm Pharmaceuticals stock Rhythm Pharmaceuticals (RYTM) recently reported six month interim Phase 2 data for setmelanotide in Prader Willi ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643024272?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-15 02:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643024272","market":"us","top_or_hot":-1,"title":"Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementPhase 2 PWS data and what it could mean for Rhythm Pharmaceuticals stock Rhythm Pharmaceuticals (RYTM) recently reported six month interim Phase 2 data for setmelanotide in Prader Willi ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-15 02:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementPhase 2 PWS data and what it could mean for Rhythm Pharmaceuticals stock Rhythm Pharmaceuticals (RYTM) recently reported six month interim Phase 2 data for setmelanotide in Prader Willi ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws","article_id":"2643024272","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-stock-after-positive-phase-2-pws","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643024272","pubTimestamp":1781460825,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Phase 2 PWS data and what it could mean for Rhythm Pharmaceuticals stock\nRhythm Pharmaceuticals (RYTM) recently reported six month interim Phase 2 data for setmelanotide in Prader Willi syndrome, highlighting clinically meaningful changes in BMI, fat mass, hyperphagia, and anxiety, and outlined plans to move into Phase 3 development.\nSee our latest analysis for Rhythm Pharmaceuticals.\nThe latest PWS data arrives after a mixed share price stretch, with the stock down 15.84% year to date on a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","RYTM":"Rhythm Pharmaceuticals Inc.","PWS":"Pacer WealthShield ETF","BK4588":"碎股"},"translate_title":"Rhythm Pharmaceuticals(RYTM)股票在第二阶段PWS数据积极后估值表明什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":1.5,"PWS":1.5},"content_text":"AdvertisementPhase 2 PWS data and what it could mean for Rhythm Pharmaceuticals stock Rhythm Pharmaceuticals (RYTM) recently reported six month interim Phase 2 data for setmelanotide in Prader Willi syndrome, highlighting clinically meaningful changes in BMI, fat mass, hyperphagia, and anxiety, and outlined plans to move into Phase 3 development. See our latest analysis for Rhythm Pharmaceuticals. The latest PWS data arrives after a mixed share price stretch, with the stock down 15.84% year to date on a share price return basis but posting a 40.51% total shareholder return over the past year, suggesting longer term enthusiasm has outweighed recent volatility. If this kind of clinical progress has your attention, it can also be worth scanning other rare disease and biotech opportunities through the 40 healthcare AI stocks With Rhythm shares down 15.84% year to date, but up 40.51% over the past year and trading at $88.38 compared with an analyst price target of $138.20, should you see untapped value here, or has the market already priced in future growth? Most Popular Narrative: 36% Undervalued At a last close of $88.38 versus a narrative fair value of $138.20, Rhythm is framed as materially undervalued, with that gap resting on bullish long term assumptions.  Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader-Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years.  Read the complete narrative. Curious what sits behind that optimism? The narrative leans on aggressive revenue expansion, margin uplift, and a rich future earnings multiple to back into its fair value. Result: Fair Value of $138.20 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that optimism can crack quickly if high R&D spending keeps Rhythm in heavy losses or if fresh safety or efficacy questions slow the broader use of setmelanotide. Find out about the key risks to this Rhythm Pharmaceuticals narrative. Another angle on valuation That narrative fair value of $138.20 leans heavily on future earnings forecasts, yet Rhythm is still loss making today with a net income loss of $207.84 million. Our DCF model presents a higher valuation scenario, with an estimated future cash flow value of $483.85 per share compared with the current $88.38 price. This raises a simple question: how comfortable are you with the assumptions needed for either view? Look into how the SWS DCF model arrives at its fair value. RYTM Discounted Cash Flow as at Jun 2026Next Steps Seen the mix of optimism and caution so far and wondering what it really adds up to for you? Act while the data and sentiment are fresh by reviewing the potential upsides in detail through the 3 key rewards Looking for more investment ideas? Do not stop with a single stock. Widen your watchlist now so you are not looking back later wishing you had acted when the data was right in front of you.  Spot potential long term value plays by scanning companies that look mispriced against their fundamentals through the 44 high quality undervalued stocks. Secure more dependable income streams by reviewing companies with higher yields and payout resilience using the 8 dividend fortresses. Sleep easier at night by focusing on companies that combine resilience with lower overall risk scores via the 71 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643024272","isCrawlerRequest":true}